Tigecycline (Tygacil)

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Intra-Abdominal Infections

Conditions

Intra-Abdominal Infections, Skin Disease, Infectious

Trial Timeline

Apr 15, 2013 → Jun 16, 2017

NCT ID

NCT01789905

About Tigecycline (Tygacil)

Tigecycline (Tygacil) is a pre-clinical stage product being developed by Pfizer for Intra-Abdominal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01789905. Target conditions include Intra-Abdominal Infections, Skin Disease, Infectious.

What happened to similar drugs?

3 of 16 similar drugs in Intra-Abdominal Infections were approved

Approved (3) Terminated (0) Active (13)

🔄Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3

🔄MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mgMerckPhase 3

🔄CXA-201 and metronidazole + MeropenemMerckPhase 3

🔄Imipenem+Cilastatin/RelebactamMerckPhase 3

🔄Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 WeeksMerckPhase 3

✅MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved

🔄MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01789905	Pre-clinical	Completed	Apr 15, 2013	Jun 16, 2017	Intra-Abdominal Infections
NCT00683332	Pre-clinical	Completed	Apr 1, 2007	May 1, 2010	Complicated Skin and Skin Structure Infections

Competing Products

20 competing products in Intra-Abdominal Infections

See all competitors

Product	Company	Stage	Hype Score
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactam	Merck	Phase 2	35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo	Merck	Phase 3	40
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mg	Merck	Phase 3	40
CXA-201 and metronidazole + Meropenem	Merck	Phase 3	40
Imipenem+Cilastatin/Relebactam	Merck	Phase 3	40
CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo	Merck	Phase 2	35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole	Merck	Phase 2	35
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 Weeks	Merck	Phase 3	40
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole	Merck	Approved	43
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks	Merck	Phase 3	40
LYS228 + Standard of care therapy	Novartis	Phase 2	27
Ceftazidime-avibactam + metronidazole + Meropenem	Pfizer	Phase 3	40
Tigecycline + Imipenem/cilastatin	Pfizer	Approved	43
ceftazidime/NXL104 + metronidazole + meropenem	Pfizer	Phase 2	35
ATM-AVI + Metronidazole	Pfizer	Phase 2	35
Ceftazidime -avibactam + Meropenem + Metronidazole	Pfizer	Phase 2	35
PF-06947386 + Metronidazole	Pfizer	Phase 3	40
Tigecycline	Pfizer	Pre-clinical	26
CAZ-AVI + Metronidazole + Meropenem	Pfizer	Phase 3	40
ATM-AVI + MTZ + MER + COL	Pfizer	Phase 3	40